LimFlow
Peripheral endovascular technology transforming the treatment of critical limb ischemia .
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
* | $250m Valuation: $250m | Acquisition | |
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 107 % | (3 %) | 18 % | 11 % | 33 % | 105 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (3774 %) | (2265 %) | (2303 %) | (2085 %) | - | (2324 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (3598 %) | (2098 %) | (2081 %) | (1870 %) | (1904 %) | (2297 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
LimFlow operates in the medical device industry, focusing on providing innovative solutions for patients suffering from Chronic Limb Threatening Ischemia (CLTI). The company’s primary product, the LimFlow Percutaneous Deep Vein Arterialization System, is designed to restore blood flow to the ischemic foot when all other treatment options have been exhausted. This minimally invasive procedure offers new hope to patients who are at risk of amputation due to severe peripheral artery disease (PAD) that has progressed to CLTI.
LimFlow serves a niche market of patients with advanced CLTI, who are often left with limited treatment options such as bypass surgery or amputation. By offering a less invasive alternative, LimFlow aims to improve patient outcomes, reduce the need for major surgeries, and enhance the quality of life for these patients.
The company operates on a business-to-business (B2B) model, partnering with hospitals, clinics, and healthcare providers to implement its technology. Revenue is generated through the sale of its medical devices and related services, including training and support for healthcare professionals.
LimFlow's market is primarily in the United States and internationally, where it is conducting clinical trials to validate the efficacy and safety of its system. The company is committed to expanding its reach and making its life-saving technology accessible to more patients globally.
Keywords: CLTI, ischemic foot, PAD, minimally invasive, blood flow restoration, medical device, healthcare, amputation prevention, clinical trials, B2B.